A5027588079- Platelet Disorders and Treatments
- Blood groups and transfusion
- Chronic Lymphocytic Leukemia Research
- Autoimmune Bullous Skin Diseases
- Venous Thromboembolism Diagnosis and Management
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Blood properties and coagulation
- Antiplatelet Therapy and Cardiovascular Diseases
- Complement system in diseases
- Blood disorders and treatments
- Erythrocyte Function and Pathophysiology
- Immunodeficiency and Autoimmune Disorders
- Renal Diseases and Glomerulopathies
- Porphyrin Metabolism and Disorders
- Lipid metabolism and disorders
- Chronic Myeloid Leukemia Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Hemoglobinopathies and Related Disorders
- Neonatal Health and Biochemistry
- Blood transfusion and management
- Monoclonal and Polyclonal Antibodies Research
- Cancer Treatment and Pharmacology
- Heme Oxygenase-1 and Carbon Monoxide
- Vascular Anomalies and Treatments
Massachusetts General Hospital
2016-2025
Harvard University
2016-2025
University of Cape Town
2009-2014
Brigham and Women's Hospital
1997-2011
Emory University
2001-2009
Roswell Park Comprehensive Cancer Center
2009
Dana-Farber Cancer Institute
2009
Memorial Sloan Kettering Cancer Center
2009
Beth Israel Deaconess Medical Center
2009
University of British Columbia
2009
Bortezomib, a boronic acid dipeptide, is novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity.In this multicenter, open-label, nonrandomized, 2 trial, we enrolled 202 patients with relapsed myeloma was refractory the therapy they had received most recently. Patients 1.3 mg of bortezomib per square meter body-surface area twice weekly for weeks, followed by week without treatment, up eight cycles (24 weeks). In suboptimal response,...
Abstract Background: Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials assist physicians management patients. Objective: These evidence-based guidelines American Society Hematology (ASH) intended support patients, clinicians, and other health care professionals their decisions about ITP. Methods: In 2015, ASH formed a multidisciplinary guideline panel that included 8 adult clinical...
Over the last decade, there have been numerous developments and changes in treatment practices for management of patients with immune thrombocytopenia (ITP). This article is an update International Consensus Report published 2010. A critical review was performed to identify all relevant articles between 2009 2018. An expert panel screened, reviewed, graded studies formulated updated consensus recommendations based on new data. The final document provides diagnosis ITP adults, during...
Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1–2 study, we administered thrombopoiesis-stimulating protein, AMG 531, to patients with ITP.
Successful renaturation of several oligomeric enzymes after denaturation by sodium dodecyl sulfate is described. The results obtained suggest a general procedure for reactivation treatment with this detergent. Proteins in solution are first incubated concentrated urea and then freed the detergent an anion exchange resin. resulting sulfate-free proteins can be renatured from standard procedures. This method has also been used to recover enzymatic activity moderate yields some electrophoresis...
ABSTRACT Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia a slight increased risk anemia evident at ≥2 weeks of linezolid treatment. Hematologic abnormalities consistent mild, reversible, duration-dependent Appropriate monitoring is warranted use.
Romiplostim, a thrombopoietin mimetic, increases platelet counts in patients with immune thrombocytopenia, few adverse effects.In this open-label, 52-week study, we randomly assigned 234 adult who had not undergone splenectomy, to receive the standard of care (77 patients) or weekly subcutaneous injections romiplostim (157 patients). Primary end points were incidences treatment failure and splenectomy. Secondary included rate response (a count >50×10(9) per liter at any scheduled visit),...
PURPOSE To assess efficacy and safety of single-agent bortezomib in previously untreated patients with multiple myeloma, investigate prevalence baseline treatment-emergent polyneuropathy, identify molecular markers associated response neuropathy. PATIENTS AND METHODS Patients received 1.3 mg/m(2) on days 1, 4, 8, 11, for up to eight 21-day cycles. A subset underwent neurophysiologic evaluation pre- post-treatment. Bone marrow aspirates were performed at exploratory whole-genome analyses....
Summary Romiplostim was effective, safe, and well‐tolerated over 6–12 months of continuous treatment in Phase 3 trials patients with immune thrombocytopenia ( ITP ). This report describes up to 5 years weekly romiplostim 292 adult a long‐term, single‐arm, open‐label study. Outcome measures included adverse events (including bleeding, thrombosis, malignancy, reticulin/fibrosis), platelet response (platelet count >50 × 10 9 per litre), the proportion requiring rescue treatments....
Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that caused activation of the classic complement pathway. Sutimlimab, humanized monoclonal antibody, selectively targets C1s protein, C1 complex serine protease responsible for activating this
Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase, may increase platelet counts in patients with immune thrombocytopenia by means dual mechanisms action: decreased macrophage (Fcγ receptor)–mediated destruction and reduced production pathogenic autoantibodies.
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of the treatment non-hematologic malignancies. Many patient-related variables (e.g., age, tumor type, number prior chemotherapy cycles, amount bone marrow involvement) determine extent CIT. CIT related to type and dose chemotherapy, with regimens containing gemcitabine, platinum, or temozolomide producing it most commonly. Bleeding need for platelet transfusions in are rather uncommon except patients counts below 25x109/L...